
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics Holdings Inc. is poised for significant growth, driven by the recent approval of new manufacturing sites in Japan alongside its joint venture, which aims to bolster production capabilities for its mRNA medicines. With clinical data expected in 2025 from its proprietary mRNA programs, there is potential for a revenue projection exceeding $500 million five years post-launch, particularly with a potential approval in the European Union that could enhance its market capitalization. Additionally, the involvement of CSL Seqirus, a seasoned vaccine developer, to lead commercialization efforts mitigates execution risks and positions Arcturus favorably within the lucrative cystic fibrosis market, which has demonstrated substantial revenue examples like TRIKAFTA.
Bears say
Arcturus Therapeutics Holdings Inc. is experiencing a negative outlook primarily due to significant revisions in revenue projections, which have been drastically lowered from $156.4 million to $11.8 million for its Kostaive product based on disappointing market estimates for COVID-19 vaccinations in Japan. In addition, the company's net loss for 4Q24 was reported at $30 million, reflecting ongoing operational challenges as it concludes the quarter with approximately $294 million in cash and equivalents, raising concerns about its ability to fund future operations. Furthermore, the overall valuation of Arcturus remains highly contingent on the success of its lead asset, ARCT-154, alongside potential delays and regulatory risks related to its mRNA therapies, which collectively contribute to a bleak financial outlook.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares